Mektovi ARRY-162 BIN-220 MEK162,比尼替尼

Binimetinib

Another Name
Mektovi， ARRY-162， BIN-220， MEK162，,比尼替尼
Indications
BRAF V600E or V600K mutation-positive metastatic melanoma.
Reg No
09 L 1194/24
Inspection No
2124-24
dosage form:Pills
Specs:15mg*180 Pills
Indate:24 month
Date：2024-10-18 Views：1263
Drug Info

COMPOSITION:

Each film-coated tablet contains Binimetinib…………………………………15mg.

INDICATION:

LuciBinim is a kinase inhibitor indicated, in combination with Encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

DOSAGE AND USE:

• Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to the initiation of LuciBinim.

• The recommended dose is 45 mg orally twice daily in combination with Encorafenib. Take LuciBinim with or without food.

• For patients with moderate or severe hepatic impairment the recommended dose is 30 mg orally twice daily.

STORAGE:

In a dry place and store at 20℃ to 25℃.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciBinim during Pregnancy and Lactation.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/binimetinib/

Related News